therapy response

You have access
The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua and Louise Emmett

Journal of Nuclear Medicine January 1, 2023, 64 (1) 69-74; DOI: https://doi.org/10.2967/jnumed.122.264104
Open Access
mCRPC Patients Receiving ²²⁵Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel O. Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Amanda Mdlophane, Alex Maes, Kgomotso Mokoala, Kgomotso Mathabe, Christophe Van, de Wiele and Alfred Morgenstern

Journal of Nuclear Medicine October 1, 2022, 63 (10) 1496-1502; DOI: https://doi.org/10.2967/jnumed.121.263618
You have access
Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
Dong-Yeon Kim, Ayoung Pyo, Misun Yun, Ramar Thangam, Sung-Hwan You, Ying Zhang, Ye-rim Jung, Dinh-Huy Nguyen, Akhil Venu, Hyeon Sik Kim, Mee Sun Yoon, Yeongjin Hong and Jung-Joon Min

Journal of Nuclear Medicine July 1, 2021, 62 (7) 956-960; DOI: https://doi.org/10.2967/jnumed.120.245290
You have access
TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng and Yansong Lin

Journal of Nuclear Medicine February 1, 2017, 58 (2) 258-265; DOI: https://doi.org/10.2967/jnumed.116.180240
You have access
Does PET SUV Harmonization Affect PERCIST Response Classification?
Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, Philippe Robin, Michael S. Hofman, David Bourhis, Jason Callahan, David S. Binns, Cédric Desmonts, Pierre-Yves Salaun, Rodney J. Hicks and Nicolas Aide

Journal of Nuclear Medicine November 1, 2016, 57 (11) 1699-1706; DOI: https://doi.org/10.2967/jnumed.115.171983
You have access
Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin α_vβ₃
Samantha Y.A. Terry, Marije I. Koenders, Gerben M. Franssen, Tapan K. Nayak, Anne Freimoser-Grundschober, Christian Klein, Wim J. Oyen, Otto C. Boerman and Peter Laverman

Journal of Nuclear Medicine March 1, 2016, 57 (3) 467-472; DOI: https://doi.org/10.2967/jnumed.115.162628
You have access
Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance
Fares Al-Ejeh, Alexander H. Staudacher, Douglas R. Smyth, Jocelyn M. Darby, Delphine Denoyer, Chris Tsopelas, Rodney J. Hicks and Michael P. Brown

Journal of Nuclear Medicine May 1, 2014, 55 (5) 772-779; DOI: https://doi.org/10.2967/jnumed.113.130559
You have access
Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models
Zhaofei Liu, Xianlei Sun, Hao Liu, Teng Ma, Jiyun Shi, Bing Jia, Huiyun Zhao and Fan Wang

Journal of Nuclear Medicine May 1, 2014, 55 (5) 818-823; DOI: https://doi.org/10.2967/jnumed.113.133660
You have access
¹⁸F-Alfatide II and ¹⁸F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy
Jinxia Guo, Ning Guo, Lixin Lang, Dale O. Kiesewetter, Qingguo Xie, Quanzheng Li, Henry S. Eden, Gang Niu and Xiaoyuan Chen

Journal of Nuclear Medicine January 1, 2014, 55 (1) 154-160; DOI: https://doi.org/10.2967/jnumed.113.122069

Main menu

User menu

Search

therapy response